High mobility group box 1 (HMGB1): potential target in sepsis-associated encephalopathy
Tani J, Morishita A, Sakamoto T, Takuma K, Nakahara M, Fujita K, Oura K, Tadokoro T, Mimura S, Nomura T, Yoneyama H, Kobara H, Himoto T, Masaki T (2021) L-carnitine reduces hospital admissions in patients with hepatic encephalopathy
Depression, as usual, however, is treated as a second-class citizen.Anesthesiologists, with their years of hands-on daily experience with ketamine and other anesthetics, rigorous training in resuscitation and titration of medications to the desired effect in individual patients, institutional obsession with patient safety, and culture of treating patients with moment-to-moment judgment rather than reliance on pharmaceutical protocols, are ideally suited to be leaders in the use of ketamine for novel applications, and in fact already have been
Contraindications and Precautions Do NOT use AOD-9604 if you: Are pregnant, trying to conceive, or breastfeeding (no safety data in pregnancy/lactation) Have active cancer or history of malignancy (peptide effects on existing cancer unknown) Are under 18 years of age (pediatric safety not established) Have known hypersensitivity to peptides or benzyl alcohol (in bacteriostatic water) Have severe kidney or liver disease without physician clearance Use with caution and enhanced monitoring if you have: Diabetes or glucose metabolism disorders (monitor blood sugar closely despite no expected impact) Cardiovascular disease (comprehensive cardiac evaluation recommended) Thyroid disorders (monitor thyroid function during therapy) History of migraines (may increase headache frequency in susceptible individuals) Drug Interactions Limited formal drug interaction studies exist for AOD-9604
